ACAD ACADIA Pharmaceuticals Inc. Stock Quote

ACAD [NASD]

Index	-	P/E	-	EPS (ttm)	-1.27	Insider Own	0.10%	Shs Outstand	161.65M	Perf Week	5.63%
Market Cap	2.65B	Forward P/E	-	EPS next Y	-0.56	Insider Trans	-10.65%	Shs Float	160.88M	Perf Month	10.28%
Income	-204.60M	PEG	-	EPS next Q	-0.19	Inst Own	92.50%	Short Float	6.01%	Perf Quarter	2.77%
Sales	512.40M	P/S	5.17	EPS this Y	41.60%	Inst Trans	0.47%	Short Ratio	3.61	Perf Half Y	-34.86%
Book/sh	2.69	P/B	6.34	EPS next Y	57.30%	ROA	-30.80%	Target Price	18.88	Perf Year	1.31%
Cash/sh	2.81	P/C	6.07	EPS next 5Y	25.00%	ROE	-41.20%	52W Range	12.24 - 28.06	Perf YTD	-26.91%
Dividend	-	P/FCF	-	EPS past 5Y	14.90%	ROI	-31.60%	52W High	-37.89%	Beta	0.72
Dividend %	-	Quick Ratio	4.50	Sales past 5Y	94.60%	Gross Margin	97.10%	52W Low	42.36%	ATR	0.82
Employees	540	Current Ratio	4.50	Sales Q/Q	16.80%	Oper. Margin	-40.30%	RSI (14)	64.33	Volatility	4.15% 5.57%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	23.10%	Profit Margin	-39.90%	Rel Volume	0.51	Prev Close	17.06
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 08 AMC	Payout	-	Avg Volume	2.68M	Price	17.42
Recom	2.60	SMA20	12.52%	SMA50	11.38%	SMA200	-14.69%	Volume	539,897	Change	2.14%

Aug-08-22

Downgrade

Citigroup

Buy → Neutral

$19 → $15

Aug-05-22

Downgrade

Citigroup

Buy → Neutral

$19 → $15

Jun-21-22

Downgrade

Jefferies

Buy → Underperform

$25 → $10

Jun-16-22

Upgrade

Jefferies

Hold → Buy

$25

Mar-16-22

Upgrade

Canaccord Genuity

Hold → Buy

$30 → $31

Feb-09-22

Upgrade

H.C. Wainwright

Neutral → Buy

$36

Jan-05-22

Upgrade

Citigroup

Neutral → Buy

$30

Dec-21-21

Downgrade

Guggenheim

Buy → Neutral

$28

Nov-01-21

Upgrade

Guggenheim

Neutral → Buy

$23

Oct-14-21

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$20

Sep-23-21

Resumed

Needham

Hold

Jun-10-21

Initiated

Berenberg

Hold

$29

Apr-07-21

Downgrade

H.C. Wainwright

Buy → Neutral

$43 → $18

Apr-06-21

Downgrade

Mizuho

Buy → Neutral

$37 → $25

Apr-06-21

Downgrade

Jefferies

Buy → Hold

$40 → $21

Apr-06-21

Downgrade

Goldman

Buy → Neutral

$73 → $25

Apr-06-21

Downgrade

Canaccord Genuity

Buy → Hold

$40 → $26

Apr-05-21

Downgrade

Raymond James

Outperform → Mkt Perform

Mar-10-21

Downgrade

BofA Securities

Buy → Neutral

Mar-09-21

Reiterated

H.C. Wainwright

Buy

$60 → $43

Aug-09-22 01:24PM	Acadia Terminates Painkiller, Cancer Candidate After Disappointing Data Benzinga
11:06AM	Acadia's (ACAD) Q2 Earnings & Revenues Surpass Estimates Zacks
Aug-08-22 05:35PM	Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM	Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results Business Wire
Aug-05-22 07:55AM	FDA Asks For Additional Study For Acadia's Pimavanserin In Alzheimer's-Associated Delusions Benzinga +5.25%
Aug-04-22 11:39PM	UPDATE 1-U.S. FDA declines to approve expanded use of Acadia's antipsychotic drug Reuters
11:05PM	Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimers Disease Psychosis Business Wire
Aug-01-22 10:01AM	Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Jul-27-22 08:23AM	Investors five-year losses grow to 52% as the stock sheds US$212m this past week Simply Wall St.
Jul-25-22 04:05PM	Acadia Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 8, 2022 Business Wire
Jul-19-22 11:22AM	Acadia (ACAD) Files an NDA for Its Rett Syndrome Candidate Zacks
Jul-18-22 04:07PM	Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome Business Wire
Jul-08-22 11:14AM	Acadia (ACAD) Down More Than 30% in Past 3 Months: Here's Why Zacks
Jun-21-22 12:07PM	Why Acadia Pharmaceuticals Stock Is Crashing Today Motley Fool -33.32%
08:27AM	Why Acadia Pharma Shares Are Plunging Today Benzinga
07:56AM	Acadia's stock down 30% in premarket trading on Tuesday after last week's FDA committee vote MarketWatch
Jun-17-22 08:00PM	Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for NUPLAZID® (pimavanserin) for the Treatment of Alzheimers Disease Psychosis Business Wire
07:14AM	Acadia Pharmaceuticals stock halted for FDA panel to review treatment for hallucinations stemming from Alzheimer's disease psychosis MarketWatch
07:05AM	Acadia Pharmaceuticals Stock Trading Halted Today Business Wire
Jun-16-22 03:42PM	HC Wainwright Sees Opportunity For Acadia's Alzheimer's Candidate Benzinga
10:42AM	Acadia (ACAD) Up on FDA Briefing Document for Nuplazid sNDA Zacks
Jun-15-22 04:53PM	Why Acadia Pharma Surged Despite A Negative FDA Take On Its Lead Drug Investor's Business Daily +15.51%
02:55PM	Why ACADIA Pharmaceuticals Shares Are Trading Higher Today? Benzinga
01:07PM	Why Acadia Pharmaceuticals Spiked Today Motley Fool
Jun-03-22 11:31AM	Why Is Acadia (ACAD) Down 13.9% Since Last Earnings Report? Zacks +10.43%
May-19-22 09:01AM	Breakeven On The Horizon For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Simply Wall St.
May-05-22 10:06AM	Acadia (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates Zacks -5.33%
May-04-22 06:15PM	Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates Zacks
04:05PM	Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results Business Wire
May-03-22 04:05PM	Acadia Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
May-02-22 04:05PM	Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting to Review Resubmission of Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimers Disease Psychosis Scheduled for June 17, 2022 Business Wire +5.97%
06:36AM	Zymeworks Inc. (ZYME) Surges 23.2%: Is This an Indication of Further Gains? Zacks
Apr-27-22 03:03PM	Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-21-22 09:09AM	9 Healthcare Stocks to Invest In Today According to Stanley Druckenmiller Insider Monkey
09:00AM	Acadia Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 4, 2022 Business Wire
Apr-19-22 05:52PM	10 Trending Stocks to Watch Today Insider Monkey
03:49PM	Analysts Say Acadia's Negative Pain Data Increases Focus On Pimavanserin For Alzheimer's-Related Psychosis Benzinga
12:02PM	Acadia (ACAD) Stock Down as Pain Candidate Misses Study Goal Zacks
06:10AM	Why Acadia Pharma Shares Are Falling Today Benzinga
Apr-18-22 04:05PM	Acadia Pharmaceuticals Announces Top-Line Results from Phase 2 Study Evaluating ACP-044 for the Treatment of Acute Postoperative Pain Business Wire
Mar-30-22 11:30AM	Why Is Acadia (ACAD) Up 1% Since Last Earnings Report? Zacks
Mar-25-22 02:26PM	Acadia Pharmaceuticals Stock Shows Market Leadership With Jump To 91 RS Rating Investor's Business Daily
Mar-22-22 09:00AM	Acadia Pharmaceuticals to Present Late-Breaking Data at the 2022 American Academy of Neurology Annual Meeting (AAN) Business Wire
Mar-10-22 04:05PM	Acadia Pharmaceuticals to Present at the 1st Annual Needham Virtual Neuroscience Forum on March 16, 2022 Business Wire
11:50AM	Acadia (ACAD) Stock Up on FDA's Action Date for Nuplazid sNDA Zacks
Mar-09-22 08:30AM	Acadia Pharmaceuticals Announces August 4, 2022 Action Date for Resubmitted Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimers Disease Psychosis Business Wire +10.17%
Mar-03-22 09:00AM	Acadia Pharmaceuticals to Present at the Cowen 42nd Annual Health Care Conference on March 9, 2022 Business Wire
Mar-01-22 09:43AM	Acadia (ACAD) Q4 Earnings & Revenues Fall Shy of Estimates Zacks
Feb-28-22 05:35PM	Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Lags Revenue Estimates Zacks
04:05PM	Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results Business Wire
Feb-21-22 03:00PM	Will Acadia Pharmaceuticals (ACAD) Report Negative Earnings Next Week? What You Should Know Zacks
Feb-17-22 04:28AM	The past year for ACADIA Pharmaceuticals (NASDAQ:ACAD) investors has not been profitable Simply Wall St.
Feb-16-22 09:00AM	Acadia Pharmaceuticals Announces Resubmission of Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) to Treat Alzheimers Disease Psychosis Business Wire
08:30AM	Here's How Much a $1000 Investment in Acadia Pharmaceuticals Made 10 Years Ago Would Be Worth Today Zacks
Feb-14-22 09:00AM	Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022 Business Wire
Feb-11-22 09:00AM	Acadia Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022 Business Wire
Feb-02-22 01:38PM	Emerald Advisers, Llc Buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA Pharmaceuticals ... GuruFocus.com
01:38PM	Emerald Mutual Fund Advisers Trust Buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA ... GuruFocus.com
Jan-13-22 11:13AM	Acadia (ACAD) Up More Than 20% in Past 3 Months: Here's Why Zacks
Jan-11-22 11:56AM	Acadia (ACAD) Partners With Stoke for CNS Disorder Therapies Zacks
Jan-10-22 01:20PM	RNA startup inks deal worth up to $967M American City Business Journals
07:00AM	Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases Business Wire
Dec-22-21 05:24PM	Why Acadia Pharmaceuticals Stock Climbed More Than 10% Wednesday Motley Fool +11.52%
09:00AM	Acadia Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022 Business Wire
Dec-21-21 04:12PM	Why This Acadia Pharmaceuticals Move Has Analysts Split And Shares Down 20% Investor's Business Daily -20.82%
11:29AM	ACADIA (ACAD) Up on Resubmission Plan for Nuplazid sNDA to FDA Zacks
Dec-20-21 04:05PM	Acadia Pharmaceuticals Announces Plan for a Resubmission of its Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) Business Wire +5.16%
Dec-14-21 09:00AM	Acadia Pharmaceuticals Announces Promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer Business Wire
Dec-11-21 05:38AM	Penn Series Small Cap Growth Fund Buys Core & Main Inc, Clear Secure Inc, Inotiv Inc, Sells ... GuruFocus.com
Dec-08-21 08:35AM	Biotech Stock Roundup: ACAD Up on Study Results, BHVN's Pipeline Update & More Zacks
Dec-07-21 12:29PM	ACADIA's (ACAD) Rett Syndrome Candidate Meets Goal in Study Zacks +9.90%
08:33AM	Why Acadia Pharmaceuticals Stock Is Rocketing Today Motley Fool
07:25AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday InvestorPlace
Dec-06-21 05:23PM	Acadia Pharmaceuticals Stock Sprints After Rett Syndrome Drug Scores A Testing Win Investor's Business Daily
04:05PM	Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome Business Wire
Dec-01-21 09:00AM	The Lancet Psychiatry Publishes Results from ADVANCE Study Evaluating Pimavanserin Treatment for Negative Symptoms of Schizophrenia Business Wire
Nov-26-21 03:58PM	10 Reddit Stocks that Flopped in 2021 Insider Monkey -5.01%
Nov-16-21 09:00AM	Acadia Pharmaceuticals and StoryCorps Collaborate to Launch Yours, Truly a Multicultural Storytelling Campaign to Bring Greater Awareness to Parkinsons Disease Non-Motor Symptoms Business Wire
Nov-09-21 11:08AM	ACADIA's (ACAD) Q3 Earnings and Revenues Beat Estimates Zacks +10.22%
Nov-08-21 05:25PM	Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:05PM	Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results Business Wire
Nov-02-21 09:00AM	Acadia Pharmaceuticals Presents New Dementia-Related Psychosis Real-World Outcomes Data at Psych Congress 2021 Business Wire -6.58%
Nov-01-21 04:05PM	Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial Business Wire +14.37%
Oct-29-21 01:35PM	Humana (HUM) to Post Q3 Earnings: What's in the Cards? Zacks
Oct-27-21 03:03PM	Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Zacks
01:46PM	Dynavax (DVAX) to Report Q3 Earnings: What's in the Cards? Zacks
09:00AM	Acadia Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 8, 2021 Business Wire
Oct-25-21 09:44AM	Hedge Funds Are Souring On ACADIA Pharmaceuticals Inc. (ACAD) Insider Monkey -6.36%
09:00AM	Acadia Pharmaceuticals to Present Data on Pimavanserin in Patients with Parkinsons Disease Dementia with Psychosis from the HARMONY trial at the 14th Clinical Trials on Alzheimers Disease (CTAD) Conference Business Wire
Oct-23-21 06:08AM	15 Biotech and Pharmaceutical Stocks to Buy According to Palo Alto Investors Insider Monkey
Oct-15-21 08:25AM	Analysts are Cutting Price Targets of These 10 Stocks Insider Monkey
Sep-03-21 11:31AM	Acadia (ACAD) Down 10.8% Since Last Earnings Report: Can It Rebound? Zacks
Sep-02-21 09:00AM	Acadia Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
Sep-01-21 04:05PM	Acadia Pharmaceuticals Announces Executive Leadership Change Business Wire
Aug-26-21 09:55AM	Stanley Druckenmiller is Loading Up on These 15 Stocks Insider Monkey
Aug-22-21 08:04AM	ACADIA Pharmaceuticals (NASDAQ:ACAD shareholders incur further losses as stock declines 5.1% this week, taking one-year losses to 56% Simply Wall St.
Aug-06-21 04:31PM	Acadia Pharmaceuticals Inc (ACAD) Q2 2021 Earnings Call Transcript Motley Fool
01:54PM	Lifshitz Law Firm, P.C. Announces Investigations of 3D Systems Corp. (NYSE: DDD), Acadia Pharmaceuticals, Inc. (NasdaqGS: ACAD), ChemoCentryx, Inc. (NasdaqGS: CCXI), and Peloton Interactive, Inc (NasdaqGS: PTON) GlobeNewswire
Aug-05-21 04:05PM	Acadia Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021 Business Wire -8.55%
12:53PM	ACADIA (ACAD) Q2 Earnings Beat, Revenues Miss Estimates Zacks

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schneyer Mark C.	EVP, Chief Financial Officer	Jun 09	Sale	17.91	653	11,695	3,342	Jun 10 08:51 PM
Schneyer Mark C.	EVP, Chief Financial Officer	Jun 08	Option Exercise	0.00	1,893	0	3,995	Jun 10 08:51 PM
DAVIS STEPHEN	CEO	May 02	Sale	18.18	5,483	99,691	75,875	May 03 08:58 PM
Stankovic Srdjan R.	President	May 02	Sale	18.18	2,865	52,091	55,188	May 03 08:55 PM
KIM AUSTIN D.	EVP,General Counsel, Secretary	May 02	Sale	18.18	894	16,255	16,742	May 03 08:51 PM
Teehan Brendan	EVP, COO, Head of Commercial	May 02	Sale	18.18	552	10,036	3,437	May 03 08:47 PM
Kihara James	Principal Accounting Officer	Apr 08	Sale	27.05	1,025	27,726	2,433	Apr 11 08:02 PM
Kihara James	Principal Accounting Officer	Feb 23	Option Exercise	0.00	840	0	840	Feb 25 05:45 PM
Stankovic Srdjan R.	President	Feb 23	Option Exercise	0.00	4,919	0	49,938	Feb 25 05:41 PM
Teehan Brendan	EVP, COO, Head of Commercial	Feb 23	Option Exercise	0.00	1,106	0	2,894	Feb 25 05:45 PM
DAVIS STEPHEN	CEO	Feb 23	Option Exercise	0.00	10,945	0	69,661	Feb 25 05:40 PM
KIM AUSTIN D.	EVP & General Counsel	Feb 23	Option Exercise	0.00	2,213	0	15,413	Feb 25 05:42 PM
KIM AUSTIN D.	EVP & General Counsel	Feb 23	Sale	23.80	782	18,612	14,631	Feb 25 05:42 PM
DAVIS STEPHEN	CEO	Feb 23	Sale	23.80	3,928	93,486	65,733	Feb 25 05:40 PM
Teehan Brendan	EVP, COO, Head of Commercial	Feb 23	Sale	23.80	472	11,234	2,422	Feb 25 05:45 PM
Stankovic Srdjan R.	President	Feb 23	Sale	23.80	1,501	35,724	48,437	Feb 25 05:41 PM
Kihara James	Principal Accounting Officer	Feb 23	Sale	23.80	359	8,544	481	Feb 25 05:45 PM
DAVIS STEPHEN	CEO	Jan 06	Sale	23.05	3,718	85,700	58,716	Jan 10 06:22 PM
Stankovic Srdjan R.	President	Jan 06	Sale	23.05	1,937	44,648	45,019	Jan 10 06:23 PM
KIM AUSTIN D.	EVP & General Counsel	Jan 06	Sale	23.05	574	13,231	13,200	Jan 10 06:24 PM
Teehan Brendan	EVP, COO, Head of Commercial	Jan 06	Sale	23.05	538	12,401	1,788	Jan 10 06:25 PM
Stankovic Srdjan R.	President	Nov 22	Sale	19.01	2,803	53,285	41,512	Nov 23 06:00 PM
Stankovic Srdjan R.	President	Oct 18	Sale	17.41	1,338	23,295	38,065	Oct 19 05:31 PM
DAVIS STEPHEN	CEO	Oct 18	Sale	17.41	2,963	51,586	52,906	Oct 19 05:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience